这篇综述探讨了铁死亡（一种铁依赖性细胞死亡形式）与癌症免疫疗法的创新交叉。传统的癌症治疗在功效和特异性方面面临局限性。铁死亡作为癌症生物学的新范例，针对癌细胞的代谢特性，并可能克服这些限制，增强免疫治疗。本综述的重点是通过纳米技术调节铁死亡以增强免疫治疗。它探讨了纳米颗粒调节的铁死亡癌细胞如何影响 TME 和免疫反应。还讨论了纳米颗粒通过铁死亡调节免疫反应的双重作用。此外，它还研究了纳米颗粒如何与各种免疫治疗策略相结合，以优化铁死亡诱导和癌症治疗功效。文献检索是使用 PubMed 和 Google Scholar 进行的，涵盖截至 2024 年 3 月发表的文章。该手稿强调了免疫疗法中铁死亡的前景和复杂前景。它强调需要深入了解铁死亡对免疫细胞和 TME 的影响，以开发更有效的癌症治疗方法，强调纳米颗粒在增强铁死亡和免疫疗法功效方面的潜力。它呼吁更深入地探索铁死亡的分子机制和临床潜力，以充分利用其在免疫治疗中的治疗益处。

This review explores the innovative intersection of ferroptosis, a form of iron-dependent cell death, with cancer immunotherapy. Traditional cancer treatments face limitations in efficacy and specificity. Ferroptosis as a new paradigm in cancer biology, targets metabolic peculiarities of cancer cells and may potentially overcome such limitations, enhancing immunotherapy.This review centers on the regulation of ferroptosis by nanotechnology to augment immunotherapy. It explores how nanoparticle-modulated ferroptotic cancer cells impact the TME and immune responses. The dual role of nanoparticles in modulating immune response through ferroptosis are also discussed. Additionally, it investigates how nanoparticles can be integrated with various immunotherapeutic strategies, to optimize ferroptosis induction and cancer treatment efficacy. The literature search was conducted using PubMed and Google Scholar, covering articles published up to March 2024.The manuscript underscores the promising yet intricate landscape of ferroptosis in immunotherapy. It emphasizes the need for a nuanced understanding of ferroptosis' impact on immune cells and the TME to develop more effective cancer treatments, highlighting the potential of nanoparticles in enhancing the efficacy of ferroptosis and immunotherapy. It calls for deeper exploration into the molecular mechanisms and clinical potential of ferroptosis to fully harness its therapeutic benefits in immunotherapy.